The Open UniversitySkip to content
 

An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients

Crea, F.; Fornaro, L.; Paolicchi, E.; Masi, G.; Frumento, P.; Loupakis, F.; Salvatore, L.; Cremolini, C.; Schirripa, M.; Graziano, F.; Ronzoni, M.; Ricci, V.; Farrar, W. L.; Falcone, A. and Danesi, R. (2012). An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO, 23(5) pp. 1207–13.

DOI (Digital Object Identifier) Link: https://doi.org/10.1093/annonc/mdr387
Google Scholar: Look up in Google Scholar

Abstract

Background: Despite therapeutic innovations, metastatic colorectal cancer (mCRC) is still characterized by poor prognosis and few molecular markers predict the risk of progression. Polycomb group genes (PcGs) are epigenetic modifiers involved in tumor suppressor gene silencing. PcG member EZH2 mediates gene silencing through histone-H3 lysine-27 methylation. In colorectal cancer (CRC), EZH2 overexpression predicts shorter survival. Recently, four EZH2 single-nucleotide polymorphisms (SNPs) have been described. The present study was aimed at evaluating the correlation between EZH2 SNPs and outcome parameters in mCRC patients.
Patients and methods: DNA was extracted from blood samples of 110 mCRC patients treated with first-line 5-fluorouracil, folinic acid, irinotecan (FOLFIRI) and bevacizumab. Genotyping was carried out by real-time PCR. Genotype was used to predict objective response, progression-free survival (PFS) and overall survival (OS). EZH2 messenger RNA levels were evaluated on lymphocytes of a parallel cohort of 50 CRC patients.
Results: One allelic variant (rs3757441 C/C versus C/T or T/T) was significantly associated with shorter PFS and OS (P < 0.01 and P < 0.05, respectively). At multivariate analysis, the same variant resulted an independent predictor of PFS and OS (P < 0.05). The C/C variant was associated with significantly higher EZH2 expression (P < 0.05).
Conclusion: An EZH2 SNP may be useful to predict clinical outcome in mCRC patients.

Item Type: Journal Item
Copyright Holders: 2011 The Author
ISSN: 1569-8041
Academic Unit/School: Faculty of Science, Technology, Engineering and Mathematics (STEM) > Life, Health and Chemical Sciences
Faculty of Science, Technology, Engineering and Mathematics (STEM)
Item ID: 45828
Depositing User: Francesco Crea
Date Deposited: 13 Apr 2016 13:42
Last Modified: 07 Dec 2018 10:39
URI: http://oro.open.ac.uk/id/eprint/45828
Share this page:

Metrics

Altmetrics from Altmetric

Citations from Dimensions

Actions (login may be required)

Policies | Disclaimer

© The Open University   contact the OU